An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients

Trial Profile

An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 20 Dec 2010 Actual end date changed from Oct 2009 to Nov 2009 as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2009 Planned end date changed from 1 Sep 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top